Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Decrease in Short Interest
by Tristan Rich · The Markets DailyBiorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 37,641 shares, a drop of 62.2% from the August 15th total of 99,687 shares. Based on an average daily volume of 175,579 shares, the days-to-cover ratio is presently 0.2 days. Approximately 3.2% of the company’s shares are sold short.
Biorestorative Therapies Stock Performance
Shares of Biorestorative Therapies stock traded down $0.06 on Tuesday, reaching $2.64. 9,527 shares of the company’s stock were exchanged, compared to its average volume of 356,215. The firm’s 50-day moving average is $4.74 and its two-hundred day moving average is $5.42. The company has a market capitalization of $3.64 million, a P/E ratio of -0.12 and a beta of 0.83. Biorestorative Therapies has a 52 week low of $2.61 and a 52 week high of $34.60.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.
Check Out Our Latest Report on BRTX
About Biorestorative Therapies
Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.
Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.